Cancer Fund
Impact investorActively deployingPhoenix · Seed–Series C · 9 people tracked
Investment thesis
Cancer Fund backs early-stage oncology companies, focusing on pre-clinical and early-clinical innovations primarily at the Seed through Series A stages. It invests through Cancer Fund I, LLC, a 10-year fund term vehicle open to verified accredited investors, and complements this with a venture-giving donor-advised fund allowing anyone to support cancer innovation. The firm emphasizes patient capital at the earliest stages to fund proof points that unlock later development, and is supported by a 10,000+ community of physicians, scientists, survivors, and impact investors who help evaluate and follow the companies it funds across diagnostics, therapeutics, and remote monitoring.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website
What they invest in
from 6 of 8 portfolio companiesBiotech ×4Healthtech ×4Medical Devices ×4AI & Machine Learning ×3Digital Health ×2Deep Tech ×1Hardware ×1SaaS ×1
HQs:United States×4
Investments · 8 tracked
founders shown can be your intro path
AOA Dx develops a blood-based liquid biopsy platform using mass spectrometry and machine learning to detect ovarian cancer at early stages through tumor-associated biomarkers in serum.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesDenver, US
Oriana Papin-Zoghbi(Founder)inAlex Fisher(Founder/COO)inAnna Jeter(Founder)inOriana Zoghbi-Harb(Executive Officer, Director)Abigail Mcelhinny(Executive Officer)
BoardSurbhi Sarna(Director)
Co-investorsAlleyCorpGood Growth CapitalJoyance PartnersY CombinatorAstiaAurum Venture Partners+18 more
Avesta Bio is a biotech company developing cancer therapeutics by targeting oxidative stress and its role in disease, based on the approach of identifying what is common across cancer cells rather than what differs.
BiotechHealthtech
Bladder cancer diagnostics (Series Seed-1)
March Bioscience is a cell therapy company assembling leading scientists and drug developers to advance cell therapy treatments.
BiotechMedical DevicesHouston, US
Sarah Hein(CEO, Co-Founder)inMaksim Mamonkin(Co-Founder, Chair Scientific Advisory Board)Malcolm Brenner(Co-founder)
BoardThomas Luby(Director)inPeter Olagunju(Director)inJoseph Petrosino(Director)
Co-investorsMission Biocapital4BIO CapitalFitz Gate VenturesModi VenturesPortal InnovationsTMC Venture Fund+1 more
NearWave develops a handheld medical device using frequency domain near infrared spectroscopy (fdNIRS) to non-invasively measure tissue oxygen saturation and hemoglobin concentrations for clinical and research applications.
AI & Machine LearningDeep TechHardwareHealthtechMedical DevicesSaaSAustin, US
Roy Stillwell(Founder)in
Co-investors1842Elevate VenturesHealth WildcattersIrishAngelsY Combinator
NXgenPort is developing a smart implantable chemotherapy port that integrates optical sensing and machine learning to monitor blood cell dynamics and other physiological changes in vivo, paired with a digital health platform for data analysis.
AI & Machine LearningDigital HealthMedical Devices
Cathy Skinner(Co-founder/Co-inventor & Chief Executive Officer)Rosanne Welcher(Co-founder/Co-inventor & Chief Operating Officer)
Co-investorsGROOVE CAPITAL
HER2 breast cancer therapeutics (Seed 2A)
Frequently asked questions
- How many investments has Cancer Fund made?
- Cancer Fund has 8 tracked investments.
- What stage does Cancer Fund invest at?
- Cancer Fund invests at the Seed, Series A, Series B, Series C stages.
- What sectors does Cancer Fund focus on?
- Cancer Fund focuses on Biotech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
- Where is Cancer Fund located?
- Cancer Fund is headquartered in Phoenix, US.
- Who does Cancer Fund co-invest with?
- Cancer Fund most often shares deals with Y Combinator, AlleyCorp, Good Growth Capital, among 30 tracked co-investors.
Images
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.
Asabys Partners is a healthcare and life sciences venture capital firm that invests in innovative science and medical technologies to improve patients' lives.
The Dementia Discovery Fund (DDF), managed by SV Health Investors, is a family of specialized venture capital funds investing exclusively in companies developing or enabling novel therapeutics for dementia, including Alzheimer's Disease.
Gilde Healthcare is a specialist investment firm managing healthcare and climate-focused funds across venture & growth, and private equity strategies with a transatlantic team of sector specialists.